Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Advancing a Novel Target Against Gastrointestinal Cancer to Undergo ADC Development in a Currently Underserved Indication

By | 8 June 2026

Delving into novel ADC target FGFR2b, MUC17 and CDH17 to treat gastrointestinal cancer, an indication currently underserved by ADC therapies
Exploring preclinical and clinical development of CDH17 ADC in colorectal cancer
Complementing bispecific design and linker-payload DAR optimization for next generation bispecific ADCs